Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Gary B Kaplan, M.D.

TitleLecturer on Psychiatry
InstitutionVeterans Affairs Boston Healthcare System
DepartmentPsychiatry
AddressBoston VA Med Ctr-Brockton
Psychiatry, 116-A
940 Belmont St
Brockton MA 02301
Phone774/826-2486
Fax508/586-0894

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Ahnallen CG. Separate and combined effects of very low nicotine cigarettes and nicotine replacement in smokers with schizophrenia and controls. Nicotine Tob Res. 2013 Jan; 15(1):121-9.
    View in: PubMed
  2. Ahnallen CG, Liverant GI, Gregor KL, Kamholz BW, Levitt JJ, Gulliver SB, Pizzagalli DA, Koneru VK, Kaplan GB. The relationship between reward-based learning and nicotine dependence in smokers with schizophrenia. Psychiatry Res. 2012 Mar 30; 196(1):9-14.
    View in: PubMed
  3. Kaplan GB, Leite-Morris KA, Fan W, Young AJ, Guy MD. Opiate sensitization induces FosB/?FosB expression in prefrontal cortical, striatal and amygdala brain regions. PLoS One. 2011; 6(8):e23574.
    View in: PubMed
  4. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Reid N. Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. Psychopharmacology (Berl). 2011 Sep; 217(2):279-87.
    View in: PubMed
  5. Kaplan GB, Moore KA. The use of cognitive enhancers in animal models of fear extinction. Pharmacol Biochem Behav. 2011 Aug; 99(2):217-28.
    View in: PubMed
  6. Kaplan GB, Vasterling JJ, Vedak PC. Brain-derived neurotrophic factor in traumatic brain injury, post-traumatic stress disorder, and their comorbid conditions: role in pathogenesis and treatment. Behav Pharmacol. 2010 Sep; 21(5-6):427-37.
    View in: PubMed
  7. Kaplan GB, Heinrichs SC, Carey RJ. Treatment of addiction and anxiety using extinction approaches: neural mechanisms and their treatment implications. Pharmacol Biochem Behav. 2011 Jan; 97(3):619-25.
    View in: PubMed
  8. Sirota AD, Rohsenow DJ, Mackinnon SV, Martin RA, Eaton CA, Kaplan GB, Monti PM, Tidey JW, Swift RM. Intolerance for Smoking Abstinence Questionnaire: psychometric properties and relationship to tobacco dependence and abstinence. Addict Behav. 2010 Jul; 35(7):686-93.
    View in: PubMed
  9. Heinrichs SC, Leite-Morris KA, Carey RJ, Kaplan GB. Baclofen enhances extinction of opiate conditioned place preference. Behav Brain Res. 2010 Mar 5; 207(2):353-9.
    View in: PubMed
  10. Kaplan GB, Leite-Morris KA, Klufas MA, Fan W. Intra-VTA adenosine A1 receptor activation blocks morphine stimulation of motor behavior and cortical and limbic Fos immunoreactivity. Eur J Pharmacol. 2009 Jan 14; 602(2-3):268-76.
    View in: PubMed
  11. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Adolfo AB. Effects of smoking abstinence, smoking cues and nicotine replacement in smokers with schizophrenia and controls. Nicotine Tob Res. 2008 Jun; 10(6):1047-56.
    View in: PubMed
  12. Rohsenow DJ, Monti PM, Hutchison KE, Swift RM, MacKinnon SV, Sirota AD, Kaplan GB. High-dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smoking. Exp Clin Psychopharmacol. 2007 Feb; 15(1):81-92.
    View in: PubMed
  13. Kaplan GB, Phillips KA, Vaccaro A, Eisen JL, Posternak MA, MacAskill HS. Assessment of insight into delusional beliefs in schizophrenia using the Brown Assessment of Beliefs Scale. Schizophr Res. 2006 Feb 28; 82(2-3):279-81.
    View in: PubMed
  14. Epstein-Lubow G, Hochstadt J, Lieberman P, Kaplan GB. Speech production in schizophrenia: preliminary data regarding voice onset time. Schizophr Res. 2006 Feb 28; 82(2-3):267-9.
    View in: PubMed
  15. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM. Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. Drug Alcohol Depend. 2005 Nov 1; 80(2):259-65.
    View in: PubMed
  16. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM. Subjective and physiological responses to smoking cues in smokers with schizophrenia. Nicotine Tob Res. 2005 Jun; 7(3):421-9.
    View in: PubMed
  17. Kaplan GB, McRoberts RL, Smokler HJ. Baclofen as adjunctive treatment for a patient with cocaine dependence and schizoaffective disorder. J Clin Psychopharmacol. 2004 Oct; 24(5):574-5.
    View in: PubMed
  18. Turalba AV, Leite-Morris KA, Kaplan GB. Antipsychotics regulate cyclic AMP-dependent protein kinase and phosphorylated cyclic AMP response element-binding protein in striatal and cortical brain regions in mice. Neurosci Lett. 2004 Feb 26; 357(1):53-7.
    View in: PubMed
  19. Leite-Morris KA, Fukudome EY, Shoeb MH, Kaplan GB. GABA(B) receptor activation in the ventral tegmental area inhibits the acquisition and expression of opiate-induced motor sensitization. J Pharmacol Exp Ther. 2004 Feb; 308(2):667-78.
    View in: PubMed
  20. Kaplan GB, Leite-Morris KA, Joshi M, Shoeb MH, Carey RJ. Baclofen inhibits opiate-induced conditioned place preference and associated induction of Fos in cortical and limbic regions. Brain Res. 2003 Oct 10; 987(1):122-5.
    View in: PubMed
  21. Leite-Morris KA, Fukudome EY, Kaplan GB. Opiate-induced motor stimulation is regulated by gamma-aminobutyric acid type B receptors found in the ventral tegmental area in mice. Neurosci Lett. 2002 Jan 14; 317(3):119-22.
    View in: PubMed
  22. Rohsenow DJ, Monti PM, Hutchison KE, Swift RM, Colby SM, Kaplan GB. Naltrexone's effects on reactivity to alcohol cues among alcoholic men. J Abnorm Psychol. 2000 Nov; 109(4):738-42.
    View in: PubMed
  23. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Harmatz JS, Shader RI. Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam. J Clin Psychopharmacol. 2000 Jun; 20(3):338-46.
    View in: PubMed
  24. Kaplan GB, Leite-Morris KA, Keith DJ. Differential effects of treatment with typical and atypical antipsychotic drugs on adenylyl cyclase and G proteins. Neurosci Lett. 1999 Oct 8; 273(3):147-50.
    View in: PubMed
  25. Kaplan GB, Bharmal NH, Leite-Morris KA, Adams WR. Role of adenosine A1 and A2A receptors in the alcohol withdrawal syndrome. Alcohol. 1999 Oct; 19(2):157-62.
    View in: PubMed
  26. Weisberg SP, Kaplan GB. Adenosine receptor antagonists inhibit the development of morphine sensitization in the C57BL/6 mouse. Neurosci Lett. 1999 Apr 2; 264(1-3):89-92.
    View in: PubMed
  27. Kaplan GB, Coyle TS. Adenosine kinase inhibitors attenuate opiate withdrawal via adenosine receptor activation. Eur J Pharmacol. 1998 Nov 27; 362(1):1-8.
    View in: PubMed
  28. Leite-Morris KA, Kaplan GB, Smith JG, Sears MT. Regulation of G proteins and adenylyl cyclase in brain regions of caffeine-tolerant and -dependent mice. Brain Res. 1998 Aug 31; 804(1):52-62.
    View in: PubMed
  29. Kaplan GB, Sethi RK, McClelland EG, Leite-Morris KA. Regulation of G protein-mediated adenylyl cyclase in striatum and cortex of opiate-dependent and opiate withdrawing mice. Brain Res. 1998 Mar 30; 788(1-2):104-10.
    View in: PubMed
  30. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Cotreau MM, Harmatz JS, Shader RI. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol. 1997 Aug; 37(8):693-703.
    View in: PubMed
  31. Kaplan GB, Leite-Morris KA. Up-regulation of adenosine transporter-binding sites in striatum and hypothalamus of opiate tolerant mice. Brain Res. 1997 Jul 25; 763(2):215-20.
    View in: PubMed
  32. Kaplan GB, Sears MT. Adenosine receptor agonists attenuate and adenosine receptor antagonists exacerbate opiate withdrawal signs. Psychopharmacology (Berl). 1996 Jan; 123(1):64-70.
    View in: PubMed
  33. Kaplan GB, Leite-Morris KA, Sears MT. Alterations of adenosine A1 receptors in morphine dependence. Brain Res. 1994 Sep 19; 657(1-2):347-50.
    View in: PubMed
  34. Kaplan GB, Greenblatt DJ, Kent MA, Cotreau-Bibbo MM. Caffeine treatment and withdrawal in mice: relationships between dosage, concentrations, locomotor activity and A1 adenosine receptor binding. J Pharmacol Exp Ther. 1993 Sep; 266(3):1563-72.
    View in: PubMed
  35. Kaplan GB, Greenblatt DJ, Kent MA, Cotreau MM, Arcelin G, Shader RI. Caffeine-induced behavioral stimulation is dose-dependent and associated with A1 adenosine receptor occupancy. Neuropsychopharmacology. 1992 May; 6(3):145-53.
    View in: PubMed
  36. Kaplan GB. Neurobiological aspects of panic disorder. R I Med. 1992 May; 75(5):247-51.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Kaplan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (218) concept(s)
_
Co-Authors
See all (9) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_